Curreio, Inc. has announced a strategic partnership with PeptiDream, Inc., which has a drug discovery development platform system: PDPS (Peptide Discovery Platform System).
Structural analysis technology using Cryo-EM is one of the best technologies in the three-dimensional structural analysis of biomolecules, and was awarded the Nobel Prize in Chemistry in 2017. In particular, single particle analysis using a Cryo-EM does not require crystallization and could obtain a structure in an aqueous solution, which is a big advantage against X-ray crystallography. It has brought technological innovations for membrane proteins that were difficult to crystallize.
By combining PeptiDream’s unique drug discovery development platform system: PDPS (Peptide Discovery Platform System) and Curreio’s advanced structural analysis platform technology, the two companies will work on the next generation small molecule drug discovery based on peptide drug discovery and hit peptide compounds. We aim to expand drug discovery targets in areas where drug discovery is difficult with conventional methods, and to further improve research and development efficiency.